Phase 1 trial of the antiangiogenic peptide ATN-161 (Ac-PHSCN-NH(2)), a beta integrin antagonist, in patients with solid tumours

To evaluate the toxicity, pharmacological and biological properties of ATN-161, a five –amino-acid peptide derived from the synergy region of fibronectin, adult patients with advanced solid tumours were enrolled in eight sequential dose cohorts (0.1–16 mg kg(−1)), receiving ATN-161 administered as a...

Descripción completa

Detalles Bibliográficos
Autores principales: Cianfrocca, M E, Kimmel, K A, Gallo, J, Cardoso, T, Brown, M M, Hudes, G, Lewis, N, Weiner, L, Lam, G N, Brown, S C, Shaw, D E, Mazar, A P, Cohen, R B
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2006
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361324/
https://www.ncbi.nlm.nih.gov/pubmed/16705310
http://dx.doi.org/10.1038/sj.bjc.6603171

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361324/
https://www.ncbi.nlm.nih.gov/pubmed/16705310
http://dx.doi.org/10.1038/sj.bjc.6603171

Ejemplares similares